Nonalcoholic Steatohepatitis

DUR-928 compound continues phase 1 clinical trials

A therapeutic compound developed at Virginia Commonwealth University, which may have broad applicability in acute organ injuries and in several metabolic diseases such as nonalcoholic fatty liver disease and nonalcoholic ...

May 19, 2015
popularity20 comments 0

Researchers link liver disease and drug metabolism

Researchers at the University of Arizona College of Pharmacy have discovered that nonalcoholic steatohepatitis (NASH), an increasingly common but often undiagnosed liver disease, could have significant medical implications ...

Jul 09, 2015
popularity12 comments 0

Non-alcoholic fatty liver disease (NAFLD) is one cause of a fatty liver, occurring when fat is deposited (steatosis) in the liver not due to excessive alcohol use. It is related to insulin resistance and the metabolic syndrome and may respond to treatments originally developed for other insulin-resistant states (e.g. diabetes mellitus type 2) such as weight loss, metformin and thiazolidinediones. Non-alcoholic steatohepatitis (NASH) is the most extreme form of NAFLD this being regarded as a major cause of cirrhosis of the liver of unknown cause.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

People with alcohol dependency lack important enzyme

A research group under the leadership of Linköping University Professor Markus Heilig has identified an enzyme whose production is turned off in nerve cells of the frontal lobe when alcohol dependence develops. The deficiency ...